We are live on !
Find out more
Persistent Asset Partners Portfolio holdings
AUM
$335M
Turnover
79.96%
1-Year Est. Return
275.57%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
(+13%)
Cap. Flow
-$5.94M
Cap. Flow % of AUM
Cap. Flow %
-4.4%
Top 10 Holdings %
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74
Avg Time Held
Equity + Options
0.2
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$4.21M |
| 2 |
Amgen
AMGN
|
+$3.4M |
| 3 |
Encompass Health
EHC
|
+$3.34M |
| 4 |
Soleno Therapeutics
SLNO
|
+$3.29M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$1.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$10.3M |
| 2 |
UnitedHealth
UNH
|
+$4.9M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$3.17M |
| 4 |
iShares Bitcoin Trust
IBIT
|
+$3M |
| 5 |
Concentra Group Holdings
CON
|
+$2.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.79% |
| 2 | Miscellaneous | 20.95% |
| 3 | Financials | 16.59% |
| 4 | Materials | 5% |
| 5 | Technology | 2.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
iShares Bitcoin Trust
IBIT
$59B
| $5.94M | 4.4% |
97,000
-53,623
| -36% | -$3M |
2025 Q1
1 quarter
|
|
2
PUT
Capricor Therapeutics
CAPR
$531M
| $5.48M | 4.06% |
+65,650
| New | +$693K |
2025 Q2
0 quarters
|
|
|
3
DELISTED
Soleno Therapeutics
SLNO
| $5.47M | 4.06% |
65,319
+43,898
| +205% | +$3.29M |
2024 Q4
2 quarters
|
|
|
4
Humana
HUM
$52.6B
| $4.91M | 3.64% |
20,069
+16,899
| +533% | +$4.21M |
2024 Q4
2 quarters
|
|
5
Pennant Group
PNTG
$1.27B
| $4.18M | 3.1% |
139,906
-29,303
| -17% | -$804K |
2024 Q4
2 quarters
|
|
|
6
Encompass Health
EHC
$13.9B
| $3.58M | 2.66% |
+29,226
| New | +$3.34M |
2025 Q2
0 quarters
|
|
|
7
Amgen
AMGN
$251B
| $3.35M | 2.49% |
+12,000
| New | +$3.4M |
2025 Q2
0 quarters
|
|
8
PUT
Corcept Therapeutics
CORT
$7.77B
| $3.31M | 2.46% |
128,368
+128,022
| +37,001% | +$9.28M |
2024 Q4
2 quarters
|
|
9
Alignment Healthcare
ALHC
$1.6B
| $3.19M | 2.37% |
227,889
-36,066
| -14% | -$581K |
2024 Q4
2 quarters
|
|
10
TG Therapeutics
TGTX
$9.7B
| $3.08M | 2.28% |
85,580
+49,508
| +137% | +$1.84M |
2024 Q4
2 quarters
|
|
11
Neurocrine Biosciences
NBIX
$17B
| $2.72M | 2.02% |
21,625
+7,321
| +51% | +$840K |
2024 Q4
2 quarters
|
|
12
Eli Lilly
LLY
$1.28T
| $2.65M | 1.97% |
3,404
-1,084
| -24% | -$842K |
2024 Q4
2 quarters
|
|
13
Jazz Pharmaceuticals
JAZZ
$15.7B
| $2.55M | 1.89% |
24,028
+4,004
| +20% | +$435K |
2025 Q1
1 quarter
|
|
|
14
BioMarin Pharmaceuticals
BMRN
$11.1B
| $2.43M | 1.8% |
44,264
+32,181
| +266% | +$1.9M |
2024 Q4
2 quarters
|
|
15
Cardinal Health
CAH
$64B
| $2.28M | 1.69% |
13,598
-1,144
| -8% | -$170K |
2024 Q4
2 quarters
|
|
16
Tenet Healthcare
THC
$23B
| $2.2M | 1.63% |
+12,521
| New | +$1.88M |
2025 Q2
0 quarters
|
|
17
DELISTED
Enhabit
EHAB
| $1.99M | 1.47% |
205,983
-81,140
| -28% | -$749K |
2024 Q4
2 quarters
|
|
18
NexGen Energy
NXE
$5.58B
| $1.93M | 1.43% |
278,082
+19,443
| +8% | +$110K |
2024 Q4
2 quarters
|
|
19
Center Bancorp
CNOB
$1.66B
| $1.89M | 1.41% |
81,814
-2,358
| -3% | -$53.8K |
2024 Q4
2 quarters
|
|
20
DELISTED
Premier
PINC
| $1.79M | 1.33% |
+81,593
| New | +$1.76M |
2025 Q2
0 quarters
|
|
21
Evolent Health
EVH
$550M
| $1.75M | 1.3% |
+155,729
| New | +$1.43M |
2025 Q2
0 quarters
|
|
22
iShares Ethereum Trust ETF
ETHA
$6.17B
| $1.64M | 1.22% |
+28,632
| New | +$1.43M |
2025 Q2
0 quarters
|
|
23
Coastal Financial
CCB
$659M
| $1.59M | 1.18% |
16,432
-5,382
| -25% | -$464K |
2024 Q4
2 quarters
|
|
24
PUT
MoonLake Immunotherapeutics
MLTX
$1.07B
| $1.48M | 1.1% |
+45,499
| New | +$1.85M |
2025 Q2
0 quarters
|
|
25
Vaxcyte
PCVX
$10.5B
| $1.48M | 1.1% |
45,499
+24,360
| +115% | +$799K |
2024 Q4
2 quarters
|
|
Similar funds
PI
SCI
WHGC
Persistent Asset Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Persistent Asset Partners withdrew a net $5.94M in Q2 2025, closing 74 positions and reducing 36 holdings. Its most notable exit was Centene, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Persistent Asset Partners opened a new position in Amgen worth $3.35M.
- Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
- Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
- Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
- Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
- Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
- Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
- Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.
Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.